Citations

Clear

949 citation(s) found for "Li, Bryan".

Trabeculectomy Bleb Characteristics in Relation to Bleb Success Using Anterior Segment Optical Coherence Tomography–A Systematic Review and Meta-Analysis
Sim, Jackie Jia Lin , Betzler, Bjorn Kaijun , Dorairaj, Syril , Dada, Tanuj , Ang, Bryan Chin Hou , Betzler, Bjorn K , Ang, Bryan C H

Mayo Clinic

Journal of Glaucoma | May 14, 2025 | Volume: 34 | Issue: 9 | Pages: 679-687

10.1097/ijg.0000000000002595 | PMID 40838860 Get It

Précis: ASOCT features of greater bleb height, thicker bleb walls, and lower reflectivity are associated with trabeculectomy success, supporting the ASOCT’s utility in monitoring and predicting outcomes postsurgery through standardized imaging protocols. Purpose: To evaluate and quantify the relationship between bleb characteristics on ASOCT with surgical outcomes. Methods: A literature search was conducted across Medline, Embase, Cochrane, and Scopus for studies from the past 20 years, until 16 September 2024, on “glaucoma,” “trabeculectomy,” and “ASOCT.” Data collected included patient characteristics, each study’s definition of bleb success, clinical outcomes, as well as bleb characteristics. A literature review was conducted on studies that could not be used for meta-analysis. Results: Eleven studies, with a pooled total of 528 eyes in 517 patients, were included in the final meta-analysis. Successful blebs had significantly higher mean bleb height [mean difference (MD) 0.38 mm, 95% CI: 0.20-0.56 mm, P=0.002], greater maximum bleb wall thickness (MD: 0.21 mm, 95% CI: 0.07-0.35 mm, P=0.009), and decreased reflectivity (MD: −48.9%, 95% CI: −78.3 to −19.4%, P=0.010), compared with failed blebs. No significant differences were found in bleb fluid cavity height and bleb area. Narrative synthesis revealed that wider blebs, increased fluid-filled cavity height, increased number of microcysts, larger filtration opening widths, and multiform bleb walls were also associated with higher rates of bleb success. Early bleb parameters were statistically significant predictors of bleb success up to 12 months postoperatively. Conclusions: Greater bleb height, thicker bleb walls, and lower reflectivity on ASOCT are consistently associated with successful trabeculectomy outcomes. The ASOCT may be useful in predicting bleb success and in supplementing postoperative monitoring, hence guiding timely medical or procedural interventions, to ensure long-term bleb success.
Robotic Assisted Bronchoscopy Management of an Intraparenchymal Emphysematous Bullae
Barrios, A., Funes‐Ferrada, Rodrigo , Valdes‐Camacho, Sofia , Fernández-Bussy, Sebastián , Abia-Trujillo, D., Barrios, A., Vaca‐Cartagena, Bryan F. , Ibrahim, Mohamed Izham Mohamed , Lee‐Mateus, Alejandra Yu

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6218-A6218

10.1164/ajrccm.2025.211.abstracts.a6218 Get It

Abstract Introduction Chronic obstructive pulmonary disease involves an unregulated inflammatory process that leads to the destruction and remodeling of lung architecture, potentially resulting in air-filled lesions known as bullae. We outline a novel technique for transbronchial decompression of a bulla using robotic-assisted bronchoscopy (RAB) in a patient with intraparenchymal emphysematous bullae. Case Description A 74-year-old woman with a medical history significant for COPD, Sjögren's disease, and former smoker, presented to our outpatient clinic with progressively worsening exertional dyspnea over the past two years. The patient underwent a thymectomy for thymic hyperplasia where a right middle bulla was incidentally identified. Posterior bullectomy was not performed intraoperatively due to severe pleural adhesions and the high risk of lung injury during dissection. High-resolution chest computed tomography revealed diffuse subpleural bullous changes, with asymmetric high-attenuation mural foci in several cysts (Figure 1A), with a total volume of 124.11 cm3. Given the high surgical risk, a bronchoscopic approach was decided. Bullae needle aspiration was performed under RAB guidance. Decompression was accomplished using PleurX catheter drainage (Pleur-Evac, Telfex, USA). The connection between the robot and the drainage system utilized a 3-way stopcock (Merit Medical Systems, USA) and a 30 cm vinyl connecting tube (Cook Incorporated, USA). Suction through water seal suction was performed at 20mmHg for 5 min, during which we observed bullae reduction with live intraprocedural mobile CT images. The robot was then retracted, and a 4.0 mm Zephyr endobronchial valve was deployed in the superior segment of the right middle lobe to promote atelectasis, no immediate complications were reported. Post-procedural chest CT demonstrated a significant reduction in bullae size as shown in Figure 1B. At the one-month follow-up, chest X-ray imaging revealed increased atelectasis and persistent collapse in the previously identified area of cystic change. By the two-month follow-up, pulmonary function tests indicated nonspecific ventilatory impairment, with improvements in FEV1% (from 70.5% to 78.2%) and FVC% (from 80.5% to 90.2% of the predicted values). Subsequent follow-ups have demonstrated clinical improvement in the patient's symptoms. Conclusion We contribute to the literature by introducing a novel, non-invasive technique for managing bullae with RAB in patients who are not candidates for surgery. Further studies are warranted to standardize this technique and assess its broader applicability. Figure 1. High-resolution computed tomography showing pre- and post-procedure views of the bullae. (A) Coronal and sagittal views showing the right middle lobe bullae. (66x81mm) (B) Post-procedure view of the chest HRCT (17x29 mm)
Prevalence of Non-cystic Fibrosis Bronchiectatic Changes in Expiratory Central Airway Collapse
Funes‐Ferrada, Rodrigo , Valdes‐Camacho, Sofia , Abia-Trujillo, D., Fernández-Bussy, Sebastián , Johnson, Margaret M. , Barrios‐Ruiz, Alanna , Lee‐Mateus, Alejandra Yu , Vaca‐Cartagena, Bryan F. , Ibrahim, Mohamed

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1974-A1974

10.1164/ajrccm.2025.211.abstracts.a1974 Get It

Abstract Background: Expiratory central airway collapse (ECAC) is defined by excessive inward bulging of either posterior tracheobronchial membrane or anterolateral cartilage. ECAC commonly coexists with COPD, asthma, GERD, and obstructive sleep apnea. ECAC association with bronchiectasis is yet to be documented. Common conditions leading to bronchiectasis are obstructive lung diseases predisposing to recurrent infections, cystic fibrosis, COPD, or idiopathic. This study aims to evaluate the occurrence of bronchiectasis in patients with ECAC as the primary outcome and the correlation between the severity of bronchiectasis and the severity of ECAC as a secondary outcome. Methods: A retrospective single-center study evaluated patients diagnosed with ECAC using dynamic bronchoscopy in Mayo Clinic, Florida, from June 2019 to December 2020. Radiologists analyzed dynamic, or non-contrast chest computed tomography (CT) scans to evaluate the presence of bronchiectatic changes and the prevalence of bronchiectasis in this population. Bronchiectatic changes were documented using the Brody scoring system which recorded the bronchiectasis size, extent and tree in bud appearance in individual lobes. The final score had a range from 0 to 72. The bronchiectasis scores for individual lung lobes were analyzed to interpret distribution of bronchiectasis in ECAC population. The combined bronchiectasis scores of severe ECAC and non-severe ECAC cohorts were compared to assess if severe ECAC had higher bronchiectatic involvement. Results: Out of the 166 patients diagnosed with ECAC through dynamic bronchoscopy, 133 patients (80.1%) presented bronchiectatic changes in their CT scans. Of the 59 patients with severe ECAC, 51 patients (86.4%) were diagnosed with bronchiectasis. Of the 107 patients with non-severe ECAC, 82 (76.6 %) had bronchiectasis. The mean bronchiectasis scores are greater in right and left lower lobes, followed by middle lobes. The median values between severe and non-severe ECAC were 3 and 3 respectively with a p value of 0.34. The inter quartile range was 9 in severe ECAC group and 6 in non-severe ECAC (graph 1). Discussion: The outcomes of this study showed a significant presence of bronchiectatic changes in the ECAC population, implying the importance of evaluating for other pathologies. It can signify a pathological process similar to other pathologies which predispose to recurrent infections except for cystic fibrosis, which has an upper lobe involvement. The correlation of severity between ECAC and bronchiectasis requires more studies with a larger cohort for significant outcomes.
Mechatronic Bio-Design and Development of an Exoskeleton to Improve Egonomics and Reduce Occupational Risks in Operators
Sanchez, Bryan , Nacarino, Adrian , Salguero, Robert Castro , Rey, Josue Alata, Cornejo, José , Vargas, Mariela , Cornejo, Jorge , Cornejo, Jose , Vargas, Mariela , Cornejo, Jorge , Rey, Josue Alata, Palomares, Ricardo

Mayo Clinic

2025 IEEE International Conference on Interdisciplinary Approaches in Technology and Management for Social Innovation (IATMSI) | May 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/iatmsi64286.2025.10985727 Get It

Safety and efficacy of MicroPulse transscleral laser therapy with the revised P3 delivery device: A randomized controlled trial
Lentz, P. Connor , Wagner, Isabella V. , Kumar, Devesh , Boopathiraj, Nithya , Ahuja, Abhimanyu S. , Checo, Leticia , Miller, Darby D. , Dorairaj, Syril , Ahuja, Abhimanyu , Checo, Leticia , Miller, Darby D , Dorairaj, Syril , Wagner, Isabella V , Lentz, P Connor , Ang, Bryan C H

Mayo Clinic

European Journal of Ophthalmology | May 8, 2025 | Volume: 35 | Issue: 5 | Pages: 1863-1874

10.1177/11206721251340102 | PMID 40336295 Get It

Objective To evaluate the safety and efficacy of MicroPulse Transscleral Laser Therapy (MicroPulse TLT) with the Revised P3 ® Delivery Device. Design Prospective, single-surgeon, interventional study in a tertiary hospital setting. Participants Sixty-two eyes of 40 patients with refractory glaucoma. Methods All subjects received 360-degree MicroPulse TLT treatment (2500 mW, 31.33% duty cycle) over a total of 240 s (8 sweeps; n = 20), 300 s (10 sweeps; n = 22), or 200 s (10 sweeps; n = 20). Participants were followed up for 6 months to assess changes in intraocular pressure (IOP), glaucoma medication burden, and best-corrected visual acuity (BCVA). Surgical success was defined as a reduction of IOP ≥ 30% from baseline and between 6–18 mmHg at last follow-up with no additional anti-glaucoma medications or secondary reinterventions. Results Surgical success was achieved in 72.7% (300 s group), 75.0% (240 s group), and 80.0% (200 s group) of eyes. Mean IOP was significantly reduced ( p < 0.001) by 49.0% (300 s group), 45.66% (240 s group), and 39.8% (200 s group) at 6 months. With all groups combined, the mean number of glaucoma medications was significantly reduced by 17.8% ( p = 0.005), and no significant changes in BCVA were observed at 6 months. Complications were minimal, including four eyes with IOP spikes, one eye with hyphema, and one eye with cystoid macular edema (CME), all of which resolved. Two eyes of the total sample (3.2%) required secondary glaucoma surgery before 6 months. Conclusions Second-generation MicroPulse TLT at fluence values of 154–229 J/cm 2 appears to be a safe and effective option for IOP reduction in refractory glaucoma.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, Rohan , Riaz, Irbaz Bin , Naqvi, Syed Arsalan Ahmed , Rumble, R. Bryan , Taplin, Mary‐Ellen , Kungel, Terry M. , Herchenhorn, Daniel , Zhang, Tian , Beckermann, Kathryn E. , Vapiwala, Neha , Celano, Paul , Hotte, Sebastién J. , Borno, Hala T. , Bryce, Alan H. , Wulff‐Burchfield, Elizabeth , He, Huan, Williams, J.E. Caerwyn , Hotte, Sebastien J , Basu, Arnab , Borno, Hala , Bryce, Alan H , Wulff-Burchfield, Elizabeth , Bodei, Lisa , Hamilton, Robert J , Emamekhoo, Hamid , Hope, Thomas A , Murad, M Hassan , Liu, Hongfang , Williams, James E , Parikh, Rahul A , Garje, Rohan , Herchenhorn, Daniel , He, Huan , Riaz, Irbaz B , Beckermann, Katy , Rumble, R Bryan , Carducci, Michael A. , Basu, Arnab , Wang, Peng , Bodei, Lisa , Loblaw, Andrew , Emamekhoo, Hamid , Hope, Thomas A. , Murad, M. Hassan , Liu, Hongfang

Mayo Clinic

Journal of Clinical Oncology | May 2, 2025 | Volume: 43 | Issue: 20 | Pages: 2311-2334

10.1200/jco-25-00007 | PMID 40315400 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .
Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Innovation and inequity in psychedelic research at the Mayo Clinic
Klim, Casimir , VanDreese, Bryan, Meyerhoefer, Terence, Breitinger, Scott , Meyerhoefer, Terence

Mayo Clinic

History of Psychiatry | April 28, 2025 | Volume: 36 | Issue: 1-3 | Pages: 3-15

10.1177/0957154x251318489 | PMID 40293719 Get It

This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and ethical practices. We highlight instances where researchers prioritized scientific progress over the autonomy, safety, and equitable treatment of research subjects, and discuss this history in the context of ongoing challenges with informed consent and equity in contemporary psychedelic research.
Isolation of Multiple Positive Cultures at Resection Arthroplasty is a Predictor of Failure Following Reimplantation
Tarabichi, Saad , Deckey, David G. , Verhey, Jens T. , Schuyver, Paul Van , Lin, Eugenia , Braithwaite, Collin , Wyles, Cody C. , Springer, Bryan D. , Van Schuyver, Paul R , Christopher, Zachary K. , Clarke, Henry D. , Spangehl, Mark J. , Wyles, Cody C , Braithwaite, Collin L , Bingham, Joshua S.

Mayo Clinic

Journal of Bone and Joint Surgery | April 24, 2025 | Volume: 107 | Issue: 12 | Pages: 1316-1323

10.2106/jbjs.24.01212 | PMID 40273213 Get It

Background: Although it is well established that the type of organism can be a risk factor for failure in patients with periprosthetic joint infection (PJI), no study to date has examined the impact of the number of positive cultures on treatment outcomes in patients undergoing 2-stage exchange. The purpose of this multicenter study was to determine the prognostic utility of multiple positive cultures at resection as a predictor of failure following reimplantation. Methods: This retrospective multicenter study identified 437 patients with chronic knee PJI who had undergone 2-stage exchange arthroplasty with a minimum of 1 year of follow-up following reimplantation. PJI was defined with use of the 2013 Musculoskeletal Infection Society (MSIS) criteria. Patients with culture-negative PJI were excluded (n = 138). Treatment failure was defined as either any reoperation for infection or PJI-related mortality. Multivariable regression controlling for risk factors for failure after a 2-stage arthroplasty was performed to determine whether ≥2 positive intraoperative cultures at resection can predict outcomes following reimplantation when compared with a single positive culture. Results: Two hundred and ninety-nine patients were included. At a mean follow-up of 6.2 ± 2.6 years, 48 patients (16.1%) experienced failure. Patients who had a failure were more likely to have had a longer interstage interval (p = 0.038) and were also more likely to have had ≥2 positive cultures at the time of resection arthroplasty (95.8% versus 75.3%; p = 0.001). On regression analysis, ≥2 positive cultures at resection was the only variable that was identified as a risk factor for failure following reimplantation in both the univariate (odds ratio [OR], 7.55 [95% CI, 2.24 to 47.0]; p = 0.006) and multivariable models (OR, 8.12 [95% CI, 2.31 to 51.9]; p = 0.005). Conclusions: This is the first study to examine the impact of the number of positive cultures on outcomes in patients with PJI. We found that the presence of ≥2 positive cultures at resection was an indicator of a poor prognosis and resulted in a greater than eightfold increase in the risk of treatment failure in patients undergoing a 2-stage exchange. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.